IELSG37 - A randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of involved mediastinal radiotherapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell
Persone
(Responsabile)
Informazioni aggiuntive
Acronimo
IELSG37
Data d'inizio
01.04.2013
Data di fine
31.03.2016
Durata
37 Mesi
Enti finanziatori
SNSF, Swiss National Science Foundation
Stato
Concluso
Categoria
Swiss National Science Foundation /
Project Funding /
Mathematics, Natural and Engineering Sciences (Division II)
